N-sulfonato-N,O-carboxymethylchitosan: A novel polymeric absorption enhancer for the oral delivery of macromolecules

Journal of Controlled Release

Volumn 117, Issue 2, 2007, Pages 171-178

  Thanou, M ^a   Henderson, S ^b   Kydonieus, A ^b   Elson, C ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Kytogenics Pharmaceuticals   (Canada)

^c SAINT MARY S UNIVERSITY   (Canada)

Author keywords

Chitosan; LMWH; Oral delivery; Reviparin; SNOCC

Indexed keywords

CHITOSAN; ORAL DELIVERY; REVIPARIN;

ABSORPTION; COMPLEXATION; CONTROLLED DRUG DELIVERY; DERIVATIVES; MACROMOLECULES; POLYELECTROLYTES;

POLYSACCHARIDES;

BLOOD CLOTTING FACTOR 10A INHIBITOR; CARBON 11; CHITOSAN DERIVATIVE; FLUORESCEIN ISOTHIOCYANATE; LOW MOLECULAR WEIGHT HEPARIN; MANNITOL; N SULFONATO N,O CARBOXYMETHYLCHITOSAN; REVIPARIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG EFFECT; DRUG FORMULATION; DRUG PENETRATION; DRUG SYNTHESIS; DRUG TRANSPORT; DRUG UPTAKE; ELECTRIC RESISTANCE; EPITHELIUM; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; INTESTINE EPITHELIUM; MACROMOLECULE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; VISCOSITY;

ADJUVANTS, PHARMACEUTIC; ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; AREA UNDER CURVE; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CHITOSAN; DEXTRANS; ELECTRIC IMPEDANCE; FLUORESCEIN-5-ISOTHIOCYANATE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INTESTINAL MUCOSA; MACROMOLECULAR SUBSTANCES; MALE; MANNITOL; MOLECULAR STRUCTURE; POLYMERS; RATS; RATS, WISTAR; SULFONIC ACIDS; SULFUR OXIDES; VISCOSITY;

EID: 33846550081     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2006.11.002     Document Type: Article

References (35)

1. Cano-Cebrian M.J., Zornoza T., Granero L., and Polache A. Intestinal absorption enhancement via the paracellular route by fatty acids, chitosans and others: a target for drug delivery. Curr. Drug Deliv. 2 1 (2005) 9-22
2. Watts T.L., and Fasano A. Modulation of intestinal permeability: a novel and innovative approach for the oral delivery of drugs, macromolecules and antigens. Biotechnol. Genet. Eng. Rev. 17 (2000) 433-453
3. Goldberg M., and Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat. Rev., Drug Discov. 2 4 (2003) 289-295
4. Lapierre L.A. The molecular structure of the tight junction. Adv. Drug Deliv. Rev. 41 3 (2000) 255-264
5. Ross B.P., and Toth I. Gastrointestinal absorption of heparin by lipidization or coadministration with penetration enhancers. Curr. Drug Deliv. 2 3 (2005) 277-287
6. de Lissovoy G. Economic issues in the treatment and prevention of deep vein thrombosis from a managed care perspective. Am. J. Manag. Care 7 17 Suppl (2001) S535-S538 (discussion S538-544)
7. Wellington K., McClellan K., and Jarvis B. Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism. Drugs 61 8 (2001) 1185-1209
8. Pineo G., Hull R., and Marder V. Oral delivery of heparin: SNAC and related formulations. Best Pract. Res. Clin. Haematol. 17 1 (2004) 153-160
9. Berkowitz S.D., Marder V.J., Kosutic G., and Baughman R.A. Oral heparin administration with a novel drug delivery agent (SNAC) in healthy volunteers and patients undergoing elective total hip arthroplasty. J. Thromb. Haemost. 1 9 (2003) 1914-1919
10. Pineo G.F., Hull R.D., and Marder V.J. Orally active heparin and low-molecular-weight heparin. Curr. Opin. Pulm. Med. 7 5 (2001) 344-348
11. Salartash K., Lepore M., Gonze M.D., Leone-Bay A., Baughman R., Sternbergh III W.C., Bowen J.C., and Money S.R. Treatment of experimentally induced caval thrombosis with oral low molecular weight heparin and delivery agent in a porcine model of deep venous thrombosis. Ann. Surg. 231 6 (2000) 789-794
12. Malkov D., Wang H.Z., Dinh S., and Gomez-Orellana I. Pathway of oral absorption of heparin with sodium N-[8-(2-hydroxybenzoyl)amino] caprylate. Pharm. Res. 19 8 (2002) 1180-1184
13. Lee Y., Nam J.H., Shin H.C., and Byun Y. Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent. Circulation 104 25 (2001) 3116-3120
14. Kim S.K., Vaishali B., Lee E., Lee S., Lee Y.K., Kumar T.S., Moon H.T., and Byun Y. Oral delivery of chemical conjugates of heparin and deoxycholic acid in aqueous formulation. Thromb. Res. 117 4 (2006) 419-427
15. Lee Y.K., Kim S.K., Lee D.Y., Lee S., Kim C.Y., Shin H.C., Moon H.T., and Byun Y. Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys. J. Control. Release 111 3 (2006) 290-298
16. Motlekar N.A., Srivenugopal K.S., Wachtel M.S., and Youan B.B. Oral delivery of low-molecular-weight heparin using sodium caprate as absorption enhancer reaches therapeutic levels. J. Drug Target. 13 10 (2005) 573-583
17. Aungst B.J. Intestinal permeation enhancers. J. Pharm. Sci. 89 4 (2000) 429-442
18. Kast C.E., Guggi D., Langoth N., and Bernkop-Schnurch A. Development and in vivo evaluation of an oral delivery system for low molecular weight heparin based on thiolated polycarbophil. Pharm. Res. 20 6 (2003) 931-936
19. Thanou M., Verhoef J.C., and Junginger H.E. Oral drug absorption enhancement by chitosan and its derivatives. Adv. Drug Deliv. Rev. 52 2 (2001) 117-126
20. Thanou M., Verhoef J.C., Nihot M.T., Verheijden J.H., and Junginger H.E. Enhancement of the intestinal absorption of low molecular weight heparin (LMWH) in rats and pigs using Carbopol 934P. Pharm. Res. 18 11 (2001) 1638-1641
21. Bernkop-Schnurch A., Kast C.E., and Guggi D. Permeation enhancing polymers in oral delivery of hydrophilic macromolecules: thiomer/GSH systems. J. Control. Release 93 2 (2003) 95-103
22. Bernkop-Schnurch A., Hoffer M.H., and Kafedjiiski K. Thiomers for oral delivery of hydrophilic macromolecular drugs. Expert Opin. Drug Deliv. 1 1 (2004) 87-98
23. Thanou M., Nihot M.T., Jansen M., Verhoef J.C., and Junginger H.E. Mono-N-carboxymethyl chitosan (MCC), a polyampholytic chitosan derivative, enhances the intestinal absorption of low molecular weight heparin across intestinal epithelia in vitro and in vivo. J. Pharm. Sci. 90 1 (2001) 38-46
24. Van Aken H., Bode C., Darius H., Diehm C., Encke A., Gulba D.C., Haas S., Hacke W., Puhl W., Quante M., Riess H., Scharf R., Schellong S., Schror T., Schulte K.L., and Tebbe U. Anticoagulation: the present and future. Clin. Appl. Thromb. Hemost. 7 3 (2001) 195-204
25. Thanou M., Florea B.I., Langemeyer M.W., Verhoef J.C., and Junginger H.E. N-trimethylated chitosan chloride (TMC) improves the intestinal permeation of the peptide drug buserelin in vitro (Caco-2 cells) and in vivo (rats). Pharm. Res. 17 1 (2000) 27-31
26. E. Hayes, N,O-carboxymethyl chitosan and preparative method therefor US4619995 (1986).
27. Q.P. Peniston, E.L. Johnson, Process for depolymerization of chitosan. US3922260 (1975).
28. Artursson P., Palm K., and Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 46 1-3 (2001) 27-43
29. Kakkar V.V., Hoppenstead D.A., Fareed J., Kadziola Z., Scully M., Nakov R., and Breddin H.K. Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis. Blood 99 6 (2002) 1965-1970
30. Breddin H.K. Reviparin sodium - a new low molecular weight heparin. Expert Opin. Pharmacother. 3 2 (2002) 173-182
31. Hiebert L.M., Wice S.M., Ping T., Herr D., and Laux V. Antithrombotic efficacy in a rat model of the low molecular weight heparin, reviparin sodium, administered by the oral route. Thromb. Haemost. 85 1 (2001) 114-118
32. Artursson P., Lindmark T., Davis S.S., and Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm. Res. 11 9 (1994) 1358-1361
33. Hidalgo I.J. Assessing the absorption of new pharmaceuticals. Curr. Top Med. Chem. 1 5 (2001) 385-401
34. Yang T., Arnold J.J., and Ahsan F. Tetradecylmaltoside (TDM) enhances in vitro and in vivo intestinal absorption of enoxaparin, a low molecular weight heparin. J. Drug Target. 13 1 (2005) 29-38
35. Jiao Y., Ubrich N., Marchand-Arvier M., Vigneron C., Hoffman M., Lecompte T., and Maincent P. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation 105 2 (2002) 230-235